[
  {
    "ts": null,
    "headline": "Vertex Says Long-Term Data Show Casgevy's 'Durable' Clinical Benefits in Blood Disorder Trials",
    "summary": "Vertex Pharmaceuticals (VRTX) said Thursday that longer term data from ongoing clinical trials show",
    "url": "https://finnhub.io/api/news?id=be0aa487e5c3d0788d55e8e6191e684218d6668043c56ec9e2ef56e81dea7de8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751564766,
      "headline": "Vertex Says Long-Term Data Show Casgevy's 'Durable' Clinical Benefits in Blood Disorder Trials",
      "id": 135740220,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals (VRTX) said Thursday that longer term data from ongoing clinical trials show",
      "url": "https://finnhub.io/api/news?id=be0aa487e5c3d0788d55e8e6191e684218d6668043c56ec9e2ef56e81dea7de8"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Presents Longer-Term Data at the 2025 European Hematology Association (EHA) Congress Demonstrating Durability of CASGEVY速 and Provides Update on Expanding Global Access to CASGEVY",
    "summary": "Vertex Pharmaceuticals (Nasdaq: VRTX) recently announced positive longer-term data for PrCASGEVY速 (exagamglogene autotemcel) from global ongoing pivotal clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, presented at the European Hematology Association (EHA) Congress, continue to demonstrate the durable clinical benefits of CASGEVY. The longest follow up in SCD patients now extends more than 5.5 years and in TDT patients",
    "url": "https://finnhub.io/api/news?id=62ec1914699c9dd77197d40ef15bd76bd5856e7a97ec716bd8a62c3e67e0726d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751549880,
      "headline": "Vertex Presents Longer-Term Data at the 2025 European Hematology Association (EHA) Congress Demonstrating Durability of CASGEVY速 and Provides Update on Expanding Global Access to CASGEVY",
      "id": 135735903,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals (Nasdaq: VRTX) recently announced positive longer-term data for PrCASGEVY速 (exagamglogene autotemcel) from global ongoing pivotal clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, presented at the European Hematology Association (EHA) Congress, continue to demonstrate the durable clinical benefits of CASGEVY. The longest follow up in SCD patients now extends more than 5.5 years and in TDT patients",
      "url": "https://finnhub.io/api/news?id=62ec1914699c9dd77197d40ef15bd76bd5856e7a97ec716bd8a62c3e67e0726d"
    }
  }
]